+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Antiparkinsonian Drugs Market - Global Forecast 2025-2030- Product Image
Oral Antiparkinsonian Drugs Market - Global Forecast 2025-2030- Product Image
Sale

Oral Antiparkinsonian Drugs Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6143438
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The oral antiparkinsonian drug market is evolving rapidly, shaped by innovation, shifting clinical guidelines, and the growing prevalence of Parkinson’s disease in aging populations. As oral therapies remain central to disease management, understanding the landscape is essential for senior leaders seeking to enhance outcomes and navigate a complex regulatory and economic environment.

Market Snapshot: Oral Antiparkinsonian Drug Market

The oral antiparkinsonian drug market demonstrates dynamic growth fueled by rising disease incidence and expanding therapeutic options. Accessible oral formulations continue to underpin treatment protocols, ensuring widespread availability for both clinicians and patients. The market benefits from ongoing advancements that drive improvements in patient adherence and care delivery, aligning with evolving clinical priorities.

Scope & Segmentation of the Oral Antiparkinsonian Drug Market

This research provides granular analysis and forecasts across all critical dimensions of the oral antiparkinsonian sector, offering actionable segmentation for strategic planning:

  • Drug Classes: Anticholinergic agents (benztropine, trihexyphenidyl), COMT inhibitors (entacapone, opicapone, tolcapone), dopamine agonists (pramipexole, ropinirole, rotigotine), multiple levodopa combinations, MAO-B inhibitors (rasagiline, selegiline), NMDA antagonists (amantadine).
  • Product Types: Branded solutions (Azilect, Mirapex, Requip, Rytary, Sinemet), generics (carbidopa-levodopa, entacapone, pramipexole, rasagiline, ropinirole).
  • Formulations: Controlled release and immediate release medications in capsules and tablets.
  • Distribution Channels: Hospital, online, and retail pharmacies—each channel offering differentiated value in care management, access, and support services.
  • Therapies: Adjunct and monotherapy regimens tailored to varying disease stages.
  • Geographies: Americas (U.S. states and countries such as Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (including the UK, Germany, France, South Africa, Saudi Arabia, and more), and Asia-Pacific (China, India, Japan, Australia, among others).
  • Company Analysis: In-depth reviews of major industry participants, such as Merck & Co., Inc., Novartis AG, Boehringer Ingelheim, Teva Pharmaceutical Industries, GlaxoSmithKline, Sandoz, Viatris, Sun Pharma, Dr. Reddy's, and Cipla.

Key Takeaways for Senior Decision-Makers

  • Emerging molecular innovations and novel delivery systems are enhancing drug bioavailability and stabilizing symptom control, directly impacting patient outcomes and therapy effectiveness.
  • Digital health tools, including smart dosing and monitoring platforms, are being integrated to promote adherence and enable data-driven care, providing clear routes to differentiation for leading organizations.
  • Regulatory agility, such as accelerated approval mechanisms, is encouraging industry collaboration and supporting the development of targeted therapies beyond symptomatic relief.
  • Companies are balancing branded advancements with cost-effective generics, ensuring broader clinical access and fostering competition in mature and developing markets.
  • Strategic regional positioning, awareness of local policy shifts, and early engagement with health technology assessment bodies are increasingly decisive in driving adoption and commercial resilience.

Tariff Impact: Navigating the 2025 U.S. Regulatory Landscape

The planned 2025 U.S. tariff adjustments on select APIs and finished dosage forms are actively reshaping both supply chains and pricing dynamics within the oral antiparkinsonian market. Manufacturers are recalibrating sourcing, negotiating long-term supply contracts with contingency planning, and evaluating domestic production incentives. Downstream stakeholders are reviewing reimbursement strategies and alternative procurement models to manage emerging cost pressures. These regulatory shifts highlight a need for agile operations and robust quality assurance throughout the distribution network.

Methodology & Data Sources

This executive summary blends secondary and primary research. Secondary sources include peer-reviewed literature, regulatory filings, and company reports. Primary interviews with clinicians, procurement executives, and supply chain leaders offer qualitative insight. Quantitative data is synthesized from proprietary and third-party databases, all validated through cross-referencing and expert feedback.

Why This Report Matters

  • Equips senior leaders with a comprehensive understanding of therapeutic and commercial trends, supporting evidence-based investment and risk management decisions.
  • Enables optimized portfolio and supply chain strategies in the context of regulatory change and regional market diversity.
  • Guides engagement with emerging technologies and regional opportunities to maximize access and patient benefit.

Conclusion

With continuous innovation and regulatory reforms shaping the landscape, the oral antiparkinsonian drug market demands informed, flexible strategies from senior decision-makers. This report delivers practical intelligence to fuel growth, resilience, and patient-centered outcomes.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of extended-release oral formulations to improve motor control fluctuations
5.2. Emerging use of pharmacogenomic profiling to tailor levodopa dosing regimens for patients
5.3. Integration of digital pill tracking and mobile apps to enhance medication adherence in Parkinson patients
5.4. Development of novel oral monoamine oxidase B inhibitors with improved blood-brain barrier penetration
5.5. Pipeline entry of sustained-release dopamine agonists targeting once-daily oral dosing convenience
5.6. Market influx of generic levodopa-carbidopa formulations driving price competition and access expansion
5.7. Growing research into gut microbiome modulation as adjunct therapy to improve oral drug efficacy
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Oral Antiparkinsonian Drugs Market, by Class
8.1. Introduction
8.2. Anticholinergic Agents
8.2.1. Benztropine
8.2.2. Trihexyphenidyl
8.3. Comt Inhibitors
8.3.1. Entacapone
8.3.2. Opicapone
8.3.3. Tolcapone
8.4. Dopamine Agonists
8.4.1. Pramipexole
8.4.2. Ropinirole
8.4.3. Rotigotine
8.5. Levodopa
8.5.1. Carbidopa-Levodopa
8.5.2. Levodopa-Entacapone
8.5.3. Levodopa-Opicapone
8.6. Mao-B Inhibitors
8.6.1. Rasagiline
8.6.2. Selegiline
8.7. Nmda Antagonists
8.7.1. Amantadine
9. Oral Antiparkinsonian Drugs Market, by Product Type
9.1. Introduction
9.2. Branded
9.2.1. Azilect
9.2.2. Mirapex
9.2.3. Requip
9.2.4. Rytary
9.2.5. Sinemet
9.3. Generic
9.3.1. Carbidopa-Levodopa Generic
9.3.2. Entacapone Generic
9.3.3. Pramipexole Generic
9.3.4. Rasagiline Generic
9.3.5. Ropinirole Generic
10. Oral Antiparkinsonian Drugs Market, by Formulation
10.1. Introduction
10.2. Controlled Release
10.2.1. Capsules
10.2.2. Tablets
10.3. Immediate Release
10.3.1. Capsules
10.3.2. Tablets
11. Oral Antiparkinsonian Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Oral Antiparkinsonian Drugs Market, by Therapy
12.1. Introduction
12.2. Adjunct Therapy
12.3. Monotherapy
13. Americas Oral Antiparkinsonian Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Oral Antiparkinsonian Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Oral Antiparkinsonian Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck & Co., Inc.
16.3.2. Novartis AG
16.3.3. Boehringer Ingelheim International GmbH
16.3.4. Teva Pharmaceutical Industries Ltd.
16.3.5. GlaxoSmithKline plc
16.3.6. Sandoz International GmbH
16.3.7. Viatris Inc.
16.3.8. Sun Pharmaceutical Industries Ltd.
16.3.9. Dr. Reddy's Laboratories Ltd.
16.3.10. Cipla Ltd.
17. Research AI18. Research Statistics19. Research Contacts20. Research Articles21. Appendix
List of Figures
FIGURE 1. ORAL ANTIPARKINSONIAN DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ORAL ANTIPARKINSONIAN DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ORAL ANTIPARKINSONIAN DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ORAL ANTIPARKINSONIAN DRUGS MARKET: RESEARCHAI
FIGURE 26. ORAL ANTIPARKINSONIAN DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. ORAL ANTIPARKINSONIAN DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. ORAL ANTIPARKINSONIAN DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ORAL ANTIPARKINSONIAN DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BENZTROPINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BENZTROPINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY TRIHEXYPHENIDYL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY TRIHEXYPHENIDYL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ENTACAPONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ENTACAPONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY OPICAPONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY OPICAPONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY TOLCAPONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY TOLCAPONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ROPINIROLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ROPINIROLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ROTIGOTINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ROTIGOTINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CARBIDOPA-LEVODOPA, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CARBIDOPA-LEVODOPA, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA-ENTACAPONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA-ENTACAPONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA-OPICAPONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA-OPICAPONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY RASAGILINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY RASAGILINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY SELEGILINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY SELEGILINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY AMANTADINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY AMANTADINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY AZILECT, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY AZILECT, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MIRAPEX, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MIRAPEX, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY REQUIP, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY REQUIP, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY RYTARY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY RYTARY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY SINEMET, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY SINEMET, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CARBIDOPA-LEVODOPA GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CARBIDOPA-LEVODOPA GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ENTACAPONE GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ENTACAPONE GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRAMIPEXOLE GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRAMIPEXOLE GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY RASAGILINE GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY RASAGILINE GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ROPINIROLE GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ROPINIROLE GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ADJUNCT THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ADJUNCT THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 189. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2018-2024 (USD MILLION)
TABLE 190. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2025-2030 (USD MILLION)
TABLE 191. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2018-2024 (USD MILLION)
TABLE 192. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2025-2030 (USD MILLION)
TABLE 193. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2018-2024 (USD MILLION)
TABLE 196. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2025-2030 (USD MILLION)
TABLE 197. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2018-2024 (USD MILLION)
TABLE 198. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2025-2030 (USD MILLION)
TABLE 199. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 200. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 201. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 202. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 203. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 204. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 205. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 206. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 207. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 208. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 209. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 210. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 211. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2024 (USD MILLION)
TABLE 212. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2025-2030 (USD MILLION)
TABLE 213. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2024 (USD MILLION)
TABLE 214. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2025-2030 (USD MILLION)
TABLE 215. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 218. CANADA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 219. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2018-2024 (USD MILLION)
TABLE 220. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2025-2030 (USD MILLION)
TABLE 221. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2018-2024 (USD MILLION)
TABLE 222. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2025-2030 (USD MILLION)
TABLE 223. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2018-2024 (USD MILLION)
TABLE 226. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2025-2030 (USD MILLION)
TABLE 227. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2018-2024 (USD MILLION)
TABLE 228. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2025-2030 (USD MILLION)
TABLE 229. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 230. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 231. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 232. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 233. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 234. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 235. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 236. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 237. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 238. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 239. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 240. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 241. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2024 (USD MILLION)
TABLE 242. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2025-2030 (USD MILLION)
TABLE 243. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2024 (USD MILLION)
TABLE 244. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2025-2030 (USD MILLION)
TABLE 245. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 248. MEXICO ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY COMT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DOPAMINE AGONISTS, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY LEVODOPA, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY MAO-B INHIBITORS, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 293. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 294. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 299. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 300. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CONTROLLED RELEASE, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 308. ARGENTINA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2018-2024 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY CLASS, 2025-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2018-2024 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE, BY ANTICHOLINERGIC AGENTS, 2025-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA ORAL ANTIPARKINSONIAN DRUGS MARKET SIZE,

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Oral Antiparkinsonian Drugs Market report include:
  • Merck & Co., Inc.
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Ltd.

Related Reports

Parkinson's Disease Seven-Market Drug Forecast and Market Analysis - Product Image

Parkinson's Disease Seven-Market Drug Forecast and Market Analysis

  • Report
  • 169 Pages
  • Global
From
Huntington's Disease Treatment Market Report by Type, Drug Type, Age, Distribution Channel, End User, and Region 2025-2033 - Product Image

Huntington's Disease Treatment Market Report by Type, Drug Type, Age, Distribution Channel, End User, and Region 2025-2033

  • Report
  • 133 Pages
  • Global
From
Parkinson's Disease Market Report and Forecast 2025-2034 - Product Image

Parkinson's Disease Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Anti-Parkinson's Disease Drugs Market - Global Forecast 2025-2030 - Product Image

Anti-Parkinson's Disease Drugs Market - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Anti-Parkinson Drugs Market Report 2025 - Product Image

Anti-Parkinson Drugs Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.